CoChat

GWAS study using DNA pooling strategy identifies association of variant rs4910623 in OR52B4 gene with anti-VEGF treatment response in age-related macular degeneration

Open access
Riaz, Moeen, Lorés-Motta, Laura, Richardson, Andrea J., Lu, Yi, Montgomery, Grant, Omar, Amer, Koenekoop, Robert K., Chen, John, Muether, Philipp, Altay, Lebriz, Schick, Tina, Fauser, Sascha, Smailhodzic, Dzenita, van Asten, Freekje, de Jong, Eiko K., Hoyng, Carel B., Burdon, Kathryn P., MacGregor, Stuart, Guymer, Robyn H., den Hollander, Anneke I., Baird, Paul N. · 2016 · Scientific Reports
Cited by 26

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Pooled DNA based GWAS to determine genetic association of SNPs with visual acuity (VA) outcome in anti-vascular endothelial growth factor (anti-VEGF) treated neovascular age-related macular degeneration (nAMD) patients. We performed pooled DNA based GWAS on 285 anti-VEGF treated nAMD patients using high density Illumina 4.3 M array. Primary outcome was change in VA in Early Treatment Diabetic Retinopathy Study (ETDRS) letters after 6 months of anti-VEGF treatment (patients who lost ≥5 ETDRS letters classified as non-responders and all remaining classified as responders). GWAS analysis identified 44 SNPs of interest: 37 with strong evidence of association (p < 9 × 10−8), 2 in drug resistance genes (p < 5 × 10−6) and 5 nonsynonymous changes (p < 1 × 10−4). In the validation phase, individual genotyping of 44 variants showed three SNPs (rs4910623 p = 5.6 × 10−5, rs323085 p = 6.5 × 10−4 and rs10198937 p = 1.30 × 10−3) remained associated with VA response at 6 months. SNP rs4910623 also associated with treatment response at 3 months (p = 1.5 × 10−3). Replication of these three SNPs in 376 patients revealed association of rs4910623 with poor VA response after 3 and 6 months of treatment (p = 2.4 × 10−3 and p = 3.5 × 10−2, respectively). Meta-analysis of both cohorts (673 samples) confirmed association of rs4910623 with poor VA response after 3 months (p = 1.2 × 10−5) and 6 months (p = 9.3 × 10−6) of treatment in nAMD patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/srep37924

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 33

  1. Gehrs, K. M., Anderson, D. H., Johnson, L. V. & Hageman, G. S. Age‐related macular degeneration—emerging pathogenetic and therapeutic concepts. Annals of medicine 38, 450–471 (2006). · DOI · Paper page
  2. Ferris, F. L. et al. Clinical classification of age-related macular degeneration. Ophthalmology 120, 844–851 (2013). · DOI · Paper page
  3. Ferrara, N. Vascular endothelial growth factor: molecular and biological aspects. Current topics in microbiology and immunology 237, 1–30 (1999).
  4. Avery, R. L. et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113(363–372), e365, doi: 10.1016/j.ophtha.2005.11.019 (2006). · DOI · Paper page
  5. Rosenfeld, P. J. et al. Ranibizumab for neovascular age-related macular degeneration. The New England journal of medicine 355, 1419–1431, doi: 10.1056/NEJMoa054481 (2006). · DOI · Paper page
  6. Fritsche, L. G. et al. A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants. Nature genetics 48, 134–143, doi: 10.1038/ng.3448 (2016). · DOI · Paper page
  7. Lorés-Motta, L. et al. A genetic variant in NRP1 is associated with worse response to ranibizumab treatment in neovascular age-related macular degeneration. Pharmacogenetics and genomics 26, 20–27 (2016). · DOI
  8. Fauser, S. & Lambrou, G. N. Genetic predictive biomarkers of anti-VEGF treatment response in patients with neovascular age-related macular degeneration. Survey of ophthalmology 60, 138–152, doi: 10.1016/j.survophthal.2014.11.002 (2015). · DOI
  9. Hagstrom, S. A. et al. VEGFR2 Gene Polymorphisms and Response to Anti-Vascular Endothelial Growth Factor Therapy in Age-Related Macular Degeneration. Ophthalmology 122, 1563–1568, doi: 10.1016/j.ophtha.2015.04.024 (2015). · DOI · Paper page
  10. Tsilimbaris, M. K., López-Gálvez, M. I., Gallego-Pinazo, R., Margaron, P. & Lambrou, G. N. Epidemiological and Clinical Baseline Characteristics as Predictive Biomarkers of Response to Anti-VEGF Treatment in Patients with Neovascular AMD. Journal of ophthalmology 2016 (2016). · DOI
  11. Marchler-Bauer, A. et al. CDD: NCBI’s conserved domain database. Nucleic acids research, gku1221 (2014). · DOI · Paper page
  12. Baylor, D. A. & Burns, M. E. Control of rhodopsin activity in vision. Eye 12(Pt 3b), 521–525, doi: 10.1038/eye.1998.140 (1998). · DOI
  13. Flower, D. R. Modelling G-protein-coupled receptors for drug design. Biochimica et biophysica acta 1422, 207–234 (1999). · DOI · Paper page
  14. Wagner, A. H. et al. Exon-level expression profiling of ocular tissues. Experimental eye research 111, 105–111, doi: 10.1016/j.exer.2013.03.004 (2013). · DOI
  15. Pronin, A. et al. Expression of olfactory signaling genes in the eye. PloS one 9, e96435 (2014). · DOI
  16. Sherva, R. et al. Genetic modifiers of Hb E/beta0 thalassemia identified by a two-stage genome-wide association study. BMC medical genetics 11, 51, doi: 10.1186/1471-2350-11-51 (2010). · DOI
  17. Solovieff, N. et al. Fetal hemoglobin in sickle cell anemia: genome-wide association studies suggest a regulatory region in the 5′ olfactory receptor gene cluster. Blood 115, 1815–1822 (2010). · DOI · Paper page
  18. Wei, P., Tang, H. & Li, D. Insights into pancreatic cancer etiology from pathway analysis of genome-wide association study data. PloS one 7, e46887 (2012). · DOI
  19. Kim, S. H. et al. Expression of human olfactory receptor 10J5 in heart aorta, coronary artery, and endothelial cells and its functional role in angiogenesis. Biochemical and biophysical research communications 460, 404–408, doi: 10.1016/j.bbrc.2015.03.046 (2015). · DOI
  20. Leveziel, N. et al. Genotypic influences on severity of exudative age-related macular degeneration. Investigative ophthalmology & visual science 51, 2620–2625 (2010). · DOI
  21. Abedi, F. et al. Variants in the VEGFA gene and treatment outcome after anti-VEGF treatment for neovascular age-related macular degeneration. Ophthalmology 120, 115–121 (2013). · DOI
  22. Francis, P. J. The influence of genetics on response to treatment with ranibizumab (Lucentis) for age-related macular degeneration: the Lucentis Genotype Study (an American Ophthalmological Society thesis). Transactions of the American Ophthalmological Society 109, 115 (2011).
  23. Pearson, J. V. et al. Identification of the genetic basis for complex disorders by use of pooling-based genomewide single-nucleotide–polymorphism association studies. The American Journal of Human Genetics 80, 126–139 (2007). · DOI
  24. Schrauwen, I. et al. A genome-wide analysis identifies genetic variants in the RELN gene associated with otosclerosis. American journal of human genetics 84, 328–338, doi: 10.1016/j.ajhg.2009.01.023 (2009). · DOI
  25. Skibola, C. F. et al. Genetic variants at 6p21. 33 are associated with susceptibility to follicular lymphoma. Nature genetics 41, 873–875 (2009). · DOI
  26. Earp, M. A. et al. Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA. Human genetics 133, 481–497 (2014). · DOI
  27. Macgregor, S., Visscher, P. M. & Montgomery, G. Analysis of pooled DNA samples on high density arrays without prior knowledge of differential hybridization rates. Nucleic Acids Research 34, e55–e55 (2006). · DOI
  28. Macgregor, S. Most pooling variation in array-based DNA pooling is attributable to array error rather than pool construction error. European Journal of Human Genetics 15, 501–504 (2007). · DOI
  29. Abedi, F. et al. Genetic influences on the outcome of anti-vascular endothelial growth factor treatment in neovascular age-related macular degeneration. Ophthalmology 120, 1641–1648, doi: 10.1016/j.ophtha.2013.01.014 (2013). · DOI
  30. Macgregor, S. et al. Highly cost-efficient genome-wide association studies using DNA pools and dense SNP arrays. Nucleic acids research 36, e35 (2008). · DOI · Paper page
  31. Lu, Y. et al. Genome-wide association study for ovarian cancer susceptibility using pooled DNA. Twin Research and Human Genetics 15, 615–623 (2012). · doi:10.1017/thg.2012.38
  32. Willer, C. J., Li, Y. & Abecasis, G. R. METAL: fast and efficient meta-analysis of genomewide association scans. Bioinformatics 26, 2190–2191, doi: 10.1093/bioinformatics/btq340 (2010). · DOI · Paper page
  33. Gregori, N. Z., Feuer, W. & Rosenfeld, P. J. Novel method for analyzing snellen visual acuity measurements. Retina 30, 1046–1050 (2010). · DOI · Paper page

Cited by

See all 26

Metadata

Authors
Riaz, M., Lorés-Motta, L., Richardson, A. J., Lu, Y., Montgomery, G., Omar, A., Koenekoop, R. K., Chen, J., Muether, P., Altay, L., Schick, T., Fauser, S., Smailhodzic, D., van Asten, F., de Jong, E. K., Hoyng, C. B., Burdon, K. P., MacGregor, S., Guymer, R. H., den Hollander, A. I., & Baird, P. N.
Venue
Scientific Reports
Published
2016-11-28
Volume
6
Issue
1
Pages
37924-37924
ISSN
2045-2322 (ISSN-L)
OpenAlex
W2558918283
Cited by
26
References
7
FWCI
3.81
Type
journal article
Language
en
Open access
gold
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.